Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
June 30, 2021

Coronavirus company news summary – Novacyt launches two new lateral flow tests – BGI and Advaite partner on Covid-19 diagnostic solutions

By Chloe Kent

Novacyt is scheduled to launch two PathFlow Covid-19 antigen lateral flow tests (LFTs), strengthening the company’s Covid-19 testing portfolio and expanding its footing in point-of-care solutions. The company is expected to initially target private market opportunities for these LFTs through its own distribution network. The new PathFlow Covid-19 antigen tests are small, instrument-free and enable safe sample collection, testing, reading and disposal by healthcare professionals or patients at their homes.

Avacta Group, a diagnostics and innovative cancer therapies developer, announced that a study found its AffiDX® antigen lateral flow test can successfully detect the Delta variant in clinical Covid-19 samples. This test also seemed to beat two other lateral flow antigen tests that are commercially available in Europe. Clinical data for Avacta’s test found it to have 100% sensitivity in detecting infectious individuals with viral loads of Ct<27 via a PCR test, where patients are considered to be contagious.

BGI Americas, a diagnostic testing solutions provider, has entered into a partnership with Advaite, a biotech company, and announced the launch of dxpartnerships.com, a hub for diagnostics companies looking for partnerships based on licensing, distribution agreements and original equipment manufacturers. The partnership is expected to add Advaite’s RapCov rapid Covid-19 test to BGI’s portfolio of diagnostic testing solutions and combine Advaite’s handheld test with its real-time fluorescent RT-PCR kit for detecting SARS-CoV-2.

Related Companies

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU